Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0789
    -0.0005 (-0.04%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2617
    -0.0005 (-0.04%)
     
  • USD/JPY

    151.3220
    -0.0500 (-0.03%)
     
  • Bitcoin USD

    69,926.22
    -476.38 (-0.68%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm

IRVINE, CA / ACCESSWIRE / November 21, 2016 / Khang & Khang LLP (the "Firm") announces a class action lawsuit against Biogen Inc. ("Biogen" or the "Company") (BIIB). Investors who purchased or otherwise acquired shares between July 23, 2014 and July 23, 2015 inclusive (the "Class Period"), are encouraged to contact the Firm prior to the December 23, 2016 lead plaintiff motion deadline.

If you purchased shares of Biogen during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The Complaint alleges that throughout the Class Period, Biogen issued false and misleading statements concerning the safety profile and growth prospects of Tecfidera, an immunosuppressant that is prescribed to treat multiple sclerosis ("MS"), and Biogen's main driver of revenues at the time. The Company publicly praised Tecfidera's attractive safety profile and solid growth trajectory, while aware that the drug weakened the immune system for MS patients, causing physicians to discontinue prescriptions of Tecfidera. On October 22, 2014, Biogen announced the death of a patient linked to Tecfidera. On April 24, 2015, the Company disclosed that the patient death announced in October 2014 was causing Tecfidera sales to grow "at an overall slower rate" but the long-term outlook "remain[ed] strong." On July 24, 2015, Biogen abruptly cut its revenue guidance in half due to a revised growth expectation for Tecfidera based on safety concerns following the patient death. When this information was disclosed to the public, Biogen's stock price decreased, thus causing investors harm.

If you wish to learn more about this lawsuit at no charge to you, or if you have any questions regarding this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in certain jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

Advertisement